Suggested remit: To appraise the clinical and cost effectiveness of ixazomib in combination with lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma in people for whom a stem cell transplant is unsuitable.
Following on from information provided to NICE by the company in May 2020 the appraisal of Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1170
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 November 2022 | Note added to the project documents |
| 15 November 2022 | Discontinued. Following on from information provided to NICE by the company in May 2020 the appraisal of Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 12 June 2020 | Suspended. Topic is suspended |
| 12 June 2020 | Note added to the project documents |
| 03 July 2018 | Note added to the project documents |
| 25 April 2018 - 24 May 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 19 September 2016 | In progress. DH referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual